Navigation Links
Debiopharm Group to Support Ascepion in the Development of Debio 1144 for the Treatment of Chinese Cancer Patients
Date:4/18/2013

LAUSANNE, Switzerland and SUZHOU, China, April 18, 2013 /PRNewswire/ --

Suzhou Ascepion Pharmaceuticals, Inc. (Ascepion), a Chinese leading biotech company focusing on the discovery and development of world-class molecular targeted innovative drugs and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies, announced today that Debiopharm will support further development in China of Debio 1144, a small molecule in preclinical development for the treatment of a large spectrum of solid tumors.

Debiopharm and Ascepion had previously signed a license agreement for the development and commercialization of Debio 1144, an orally available multikinase inhibitor. After having generated positive preclinical results with the product, Debiopharm has decided to support Ascepion for further development of Debio 1144 in China as it is well designed for the treatment of certain types of cancers that are highly represented in China. 

"This is an opportunity for Ascepion to develop an anti-cancer agent tailored to the Chinese market," said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™. "At Debiopharm we value sharing our competences with a Chinese company in view of developing a product with a potential to treat various cancers highly prevalent in emerging markets."

"The disease spectrum of the Chinese population suggests the product will be well suited for its market. Thus it holds a great promise for certain cancer types in Chinese patients," commented Dr. Shan Jiang , President and CEO of Ascepion Pharmaceuticals.

About Debio 1144

Debio 1144 is a multikinase inhibitor, which has demonstrated strong efficacy in several preclinical models. It is orally available and has a large therapeutic index.

About Suzhou Ascepion Pharmaceuticals Inc.

Based in Suzhou, China, Suzhou Ascepion Pharmaceuticals, Inc. is a leading biopharmaceutical company in China dedicated to the discovery and development of breakthrough small molecule drugs. Suzhou Ascepion Pharmaceuticals possesses a fully integrated platform and proprietary technologies for the discovery and development of small molecule therapeutics targeting signal transduction pathways in a systematic and productive manner. The company has developed a pipeline of innovative small molecule drugs for the treatment of oncology and related diseases. For additional information on Suzhou Ascepion Pharmaceuticals, please visit http://www.ascepion.com.

About Debiopharm Group™

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalized medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information about Debiopharm Group™, please visit: http://www.debiopharm.com.

Debiopharm S.A. Contact    
Mrs Beatrice Hirt
Communication Coordinator
Tel.: +41(0)21-321-01-11
Fax: +41(0)21-321-01-69
bhirt@debiopharm.com
Additional Media Contacts
In London
Maitland
Brian Hudspith
Tel: +44(0)20-7379-5151
bhudspith@maitland.co.uk

In New York
Russo Partners, LLC
Martina Schwarzkopf , Ph.D.
Account Executive
Tel: +1-212-845-4292
Fax: +1-212-845-4260
martina.schwarzkopf@russopartnersllc.com


Ascepion Contact
Ms. Min Wang
Corporate administration
Tel.: +86-512-62956001
Fax: +86-512-62956001-8004
mwang@ascepion.com



'/>"/>
SOURCE The Debiopharm Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis
2. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
3. The Japanese Cancer Association and Debiopharm Group Present Doctors Oshima and Tanaka with the 2012 JCA-Mauvernay Award for their Innovative and Outstanding Cancer Research
4. Top buyers including Atico, Coles Group Asia, Kmart, Staples, Office Depot and Target Australia pre-registered to attend Global Sources spring China Sourcing Fairs
5. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
6. Watson to Acquire Actavis Group for EUR4.25 Billion
7. CentraState and Freehold Radiology Group train physicians from China
8. Winner Medical Group Inc. to Host Second Quarter 2012 Earning Conference Call on Thursday, May 10, 2012 at 9:00 p.m. EDT
9. Okuma America Chooses The Daniel Group To Provide Customer Service Research
10. H. D. Smith Signs Three Year Prime Vendor Agreement with PharmacyGPO Buying Group
11. PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... Nov 30, 2016 Research and Markets has ... Monitoring Devices 2017 - MedCore" report to their offering. ... , , ... the skull. In healthy individuals, it is circulated though the brain and ... where the amount of CSF surrounding the brain changes significantly. ...
(Date:11/30/2016)... Research and Markets has announced the addition of the ... their offering. ... Detachable coil embolization is a minimally invasive method ... embolization treatment of cerebral aneurysms is less invasive and requires less recovery ... wall of an artery in the brain. This area bulges in the ...
(Date:11/30/2016)... Calif. , Nov. 30, 2016 Varian ... it was named America,s Most JUST Company in the ... and Forbes magazine,s inaugural "JUST 100 List." ... of the largest surveys ever conducted on attitudes towards ... months. This inaugural list ranks U.S companies against their ...
Breaking Medicine Technology:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... proudly announces the launch of its 60-day free trial program for all of ... shipping make the offer a truly hassle free experience. , FlexiSpot’s unique desktop ...
(Date:12/2/2016)... ... 02, 2016 , ... With the number of pain management programs available for ... find the one that works for them. When an inventor from Suisun City, Calif., ... and decided to share it with others. , He developed a prototype for PRO ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is proud to ... which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping ... prolonging life 6 years in the last 3 decades,” says Dr. Valentine Fuster, ...
(Date:12/2/2016)... ... , ... Sourced from the Isbre Springs beneath the 5,000 year old Hardanger ... of just 6 ppm TDS (Total Dissolved Solids) in addition to its excellent taste ... several ShopRite and FoodTown stores in NJ and received rave comments from consumers. , ...
(Date:12/2/2016)... Francisco, CA (PRWEB) , ... December 02, 2016 ... ... digitally-enabled care journeys, announced today that it has raised $6.0 million in an ... inspired by Clarify Health’s conviction that patients and their caregivers can receive far ...
Breaking Medicine News(10 mins):